NZ725161A - Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors - Google Patents
Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitorsInfo
- Publication number
- NZ725161A NZ725161A NZ725161A NZ72516115A NZ725161A NZ 725161 A NZ725161 A NZ 725161A NZ 725161 A NZ725161 A NZ 725161A NZ 72516115 A NZ72516115 A NZ 72516115A NZ 725161 A NZ725161 A NZ 725161A
- Authority
- NZ
- New Zealand
- Prior art keywords
- disorders
- treating
- cognitive
- methods
- triazolo
- Prior art date
Links
- 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 title 1
- -1 [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 150000005829 chemical entities Chemical class 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 abstract 1
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983387P | 2014-04-23 | 2014-04-23 | |
| PCT/US2015/027102 WO2015164508A1 (en) | 2014-04-23 | 2015-04-22 | Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ725161A true NZ725161A (en) | 2017-10-27 |
Family
ID=53055118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ725161A NZ725161A (en) | 2014-04-23 | 2015-04-22 | Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9932345B2 (pt-PT) |
| EP (2) | EP3597649B8 (pt-PT) |
| JP (1) | JP6626449B2 (pt-PT) |
| KR (1) | KR102471058B1 (pt-PT) |
| CN (2) | CN106459062A (pt-PT) |
| AU (2) | AU2015249753B2 (pt-PT) |
| BR (1) | BR112016024713B1 (pt-PT) |
| CA (1) | CA2938294C (pt-PT) |
| DK (2) | DK3597649T3 (pt-PT) |
| ES (2) | ES2902806T3 (pt-PT) |
| HR (1) | HRP20212035T1 (pt-PT) |
| HU (1) | HUE057317T2 (pt-PT) |
| IL (2) | IL248292A (pt-PT) |
| MA (1) | MA50375A (pt-PT) |
| MX (1) | MX358004B (pt-PT) |
| NZ (1) | NZ725161A (pt-PT) |
| PL (1) | PL3597649T3 (pt-PT) |
| PT (1) | PT3597649T (pt-PT) |
| RU (1) | RU2659070C9 (pt-PT) |
| SG (1) | SG11201606216UA (pt-PT) |
| SI (1) | SI3597649T1 (pt-PT) |
| TW (1) | TWI664181B (pt-PT) |
| WO (1) | WO2015164508A1 (pt-PT) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3597649T3 (da) | 2014-04-23 | 2022-01-10 | Dart Neuroscience Llc | Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer |
| SG11201701315VA (en) | 2014-08-28 | 2017-03-30 | Asceneuron Sa | Glycosidase inhibitors |
| TWI568737B (zh) * | 2014-11-05 | 2017-02-01 | 達特神經科學（開曼）有限責任公司 | 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物 |
| CA3001768C (en) * | 2015-11-02 | 2022-12-13 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound |
| KR20180132060A (ko) | 2016-02-25 | 2018-12-11 | 아셰뉴론 에스아 | 피페라진 유도체의 산 부가 염 |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| CA3012624A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| CN108884077A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| EA039102B1 (ru) * | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| AU2017353310B2 (en) | 2016-11-02 | 2021-08-12 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as PDE2 inhibitors |
| MA46690A (fr) * | 2016-11-02 | 2019-09-11 | Janssen Pharmaceutica Nv | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 |
| WO2018109198A1 (en) | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
| MA47591A (fr) * | 2017-02-27 | 2020-01-01 | Janssen Pharmaceutica Nv | Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| CA3138307A1 (en) | 2019-05-13 | 2020-11-19 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
| TW202220992A (zh) | 2020-08-05 | 2022-06-01 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2510111A1 (fr) * | 1981-07-24 | 1983-01-28 | Roussel Uclaf | Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| HU208693B (en) | 1991-02-22 | 1993-12-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them |
| US5478825A (en) | 1991-02-22 | 1995-12-26 | Egis Gyogyszergyar | 5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives |
| US9931318B2 (en) | 2003-04-08 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
| DK1355669T3 (da) | 2000-08-10 | 2011-11-21 | Cold Spring Harbor Lab | Forbedret kognitiv træning |
| DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
| DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| FR2832711B1 (fr) * | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| EP1597386A1 (en) | 2002-11-13 | 2005-11-23 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
| US20070275961A1 (en) * | 2003-06-04 | 2007-11-29 | Vernalis (Cambridge) Limited. | Triazolo ' 1, 5-A ! Pyrimidines and Their Use in Medicine |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| AU2005279221C9 (en) | 2004-09-02 | 2012-08-23 | Takeda Gmbh | Triazolophthalazines |
| JP5130053B2 (ja) | 2005-01-05 | 2013-01-30 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | トリアゾロフタラジン |
| CN101103033B (zh) | 2005-01-05 | 2010-08-04 | 尼科梅德有限责任公司 | 作为pde2抑制剂的三唑并酞嗪 |
| US7868016B2 (en) | 2005-07-13 | 2011-01-11 | Baxter International Inc. | Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
| CN101321758A (zh) * | 2005-10-03 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 用于治疗哮喘和慢性阻塞性肺病的新5,6－二氢吡唑并[3,4－e][1,4]二氮杂－4(1H)－酮衍生物 |
| KR100844125B1 (ko) | 2007-03-23 | 2008-07-04 | 한국화학연구원 | 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물 |
| EP2152275A4 (en) | 2007-05-15 | 2011-08-03 | Helicon Therapeutics Inc | METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA (SIARN) |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| WO2010054260A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| AP2011005819A0 (en) | 2009-03-31 | 2011-08-31 | Boehringer Ingelheim Int | 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators. |
| US8680116B2 (en) | 2009-07-22 | 2014-03-25 | Merck Sharp & Dohme Corp. | Quinolinone PDE2 inhibitors |
| ES2553610T3 (es) * | 2010-12-14 | 2015-12-10 | Electrophoretics Limited | Inhibidores de la caseína cinasa 1 delta (CK1delta) |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| JP5543039B2 (ja) * | 2011-02-23 | 2014-07-09 | ファイザー・インク | 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン |
| WO2012168817A1 (en) | 2011-06-07 | 2012-12-13 | Pfizer Inc. | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
| US9056863B2 (en) | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| WO2013034755A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders |
| US20130116241A1 (en) * | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| CN103183675A (zh) * | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-4抑制剂 |
| EP3026051A4 (en) * | 2013-07-24 | 2017-03-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| DK3597649T3 (da) | 2014-04-23 | 2022-01-10 | Dart Neuroscience Llc | Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer |
| TWI568737B (zh) | 2014-11-05 | 2017-02-01 | 達特神經科學（開曼）有限責任公司 | 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物 |
-
2015
- 2015-04-22 DK DK19194930.4T patent/DK3597649T3/da active
- 2015-04-22 RU RU2016143387A patent/RU2659070C9/ru active
- 2015-04-22 HR HRP20212035TT patent/HRP20212035T1/hr unknown
- 2015-04-22 EP EP19194930.4A patent/EP3597649B8/en active Active
- 2015-04-22 MX MX2016013860A patent/MX358004B/es active IP Right Grant
- 2015-04-22 ES ES19194930T patent/ES2902806T3/es active Active
- 2015-04-22 SG SG11201606216UA patent/SG11201606216UA/en unknown
- 2015-04-22 WO PCT/US2015/027102 patent/WO2015164508A1/en active Application Filing
- 2015-04-22 NZ NZ725161A patent/NZ725161A/en unknown
- 2015-04-22 ES ES15721086T patent/ES2759246T3/es active Active
- 2015-04-22 PT PT191949304T patent/PT3597649T/pt unknown
- 2015-04-22 EP EP15721086.5A patent/EP3134413B1/en active Active
- 2015-04-22 US US15/306,069 patent/US9932345B2/en active Active
- 2015-04-22 CN CN201580030165.6A patent/CN106459062A/zh active Pending
- 2015-04-22 BR BR112016024713-2A patent/BR112016024713B1/pt active IP Right Grant
- 2015-04-22 HU HUE19194930A patent/HUE057317T2/hu unknown
- 2015-04-22 PL PL19194930T patent/PL3597649T3/pl unknown
- 2015-04-22 CA CA2938294A patent/CA2938294C/en active Active
- 2015-04-22 SI SI201531770T patent/SI3597649T1/sl unknown
- 2015-04-22 KR KR1020167032113A patent/KR102471058B1/ko active IP Right Grant
- 2015-04-22 MA MA050375A patent/MA50375A/fr unknown
- 2015-04-22 JP JP2016549758A patent/JP6626449B2/ja active Active
- 2015-04-22 DK DK15721086.5T patent/DK3134413T3/da active
- 2015-04-22 AU AU2015249753A patent/AU2015249753B2/en active Active
- 2015-04-22 CN CN201910367854.6A patent/CN110092788B/zh active Active
- 2015-04-23 TW TW104113093A patent/TWI664181B/zh active
-
2016
- 2016-10-10 IL IL248292A patent/IL248292A/en active IP Right Grant
-
2017
- 2017-08-30 IL IL254224A patent/IL254224B/en active IP Right Grant
-
2018
- 2018-02-26 US US15/905,672 patent/US10501465B2/en active Active
-
2019
- 2019-11-25 US US16/694,869 patent/US11186582B2/en active Active
- 2019-12-20 AU AU2019283994A patent/AU2019283994C1/en active Active
-
2022
- 2022-06-27 US US17/850,668 patent/US20230192698A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ725161A (en) | Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors | |
| MX2023004603A (es) | Compuestos de furanopirimidina sustituida como inhibidores de pde1. | |
| NZ711598A (en) | Substituted naphthyridine and quinoline compounds as mao inhibitors | |
| NZ711587A (en) | Substituted pyridine and pyrazine compounds as pde4 inhibitors | |
| WO2016130920A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| TW201613925A (en) | Imidazopyrazines as LSD1 inhibitors | |
| EP3107914B8 (en) | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use | |
| NZ703950A (en) | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds | |
| WO2013077921A3 (en) | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof | |
| GEP201706659B (en) | Novel bicyclic pyridinones | |
| MY164274A (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| EA201201274A1 (ru) | Ингибиторы протеинкиназ | |
| TN2014000326A1 (en) | Inhibitors of beta-secretase | |
| PL2771329T3 (pl) | Nowe związki di-podstawione 3,4-diamino-3-cyklobuteno- 1,2-dionu do zastosowania w leczeniu patologii, w których pośredniczą chemokiny | |
| MX2017000524A (es) | Compuestos novedosos de pirimidina sustituida. | |
| MX2015009633A (es) | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. | |
| WO2014071067A3 (en) | Treatment and diagnosis of colon cancer | |
| WO2014086453A8 (en) | Azaheterobicyclic compounds | |
| WO2014035860A8 (en) | Inhibitors of beta-secretase | |
| MX2019007803A (es) | Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2). | |
| MX2013007603A (es) | Antagonistas de hedgehog que tienen residuos que se unen al zinc. | |
| MX2017005988A (es) | Compuestos intermediarios para la produccion de ingredientes perfumantes. | |
| WO2015077535A3 (en) | Novel methods for treating neurodegenerative diseases | |
| EA201590884A1 (ru) | Способы лечения заболеваний печени | |
| WO2017035319A8 (en) | Methods for treatment of polycystic kidney disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2020 BY CPA GLOBAL Effective date: 20190307 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2021 BY CPA GLOBAL Effective date: 20200306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2022 BY CPA GLOBAL Effective date: 20210312 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2023 BY CPA GLOBAL Effective date: 20220310 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2024 BY CPA GLOBAL Effective date: 20230309 |